Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 1998 May;44:1037–1042.

Zinc gluconate and the common cold. Review of randomized controlled trials.

S Marshall 1
PMCID: PMC2277668  PMID: 9612589

Abstract

OBJECTIVE: To examine the evidence of seven randomized controlled trials (RCT) on the therapeutic effectiveness of zinc gluconate lozenges for treating the common cold. DATA SOURCES: Using the MeSH headings common cold and zinc gluconate, MEDLINE was searched from 1966 on for all published RCTs evaluating use of zinc gluconate for treating the common cold. STUDY SELECTION: For this study, only double-blind RCTs were included. SYNTHESIS: Fair evidence suggests that zinc gluconate lozenges have a therapeutic effect in treating the common cold. Starting therapy with zinc gluconate lozenges within 24 to 48 hours of onset of cold symptoms reduces the duration and severity of the cold. Patients must suck lozenges every 2 hours while awake during the cold. Minimum effective dose appears to be 13.3 mg of elemental zinc per lozenge. Evidence suggests that compounds such as citric acid, sorbitol, and mannitol bind the free zinc ion in the mouth, and this could account for variations in therapeutic benefit. Bad taste and nausea are important side effects of zinc lozenges. CONCLUSION: Evidence supports use of zinc gluconate lozenges for reducing the symptoms and duration of the common cold, but the side effects, bad taste, and therapeutic protocol might limit patient compliance.

Full text

PDF
1037

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Nakib W., Higgins P. G., Barrow I., Batstone G., Tyrrell D. A. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother. 1987 Dec;20(6):893–901. doi: 10.1093/jac/20.6.893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eby G. A. Stability constants of zinc complexes affect common cold treatment results. Antimicrob Agents Chemother. 1988 Apr;32(4):606–607. doi: 10.1128/aac.32.4.606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Farr B. M., Conner E. M., Betts R. F., Oleske J., Minnefor A., Gwaltney J. M., Jr Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob Agents Chemother. 1987 Aug;31(8):1183–1187. doi: 10.1128/aac.31.8.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Geist F. C., Bateman J. A., Hayden F. G. In vitro activity of zinc salts against human rhinoviruses. Antimicrob Agents Chemother. 1987 Apr;31(4):622–624. doi: 10.1128/aac.31.4.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Godfrey J. C., Conant Sloane B., Smith D. S., Turco J. H., Mercer N., Godfrey N. J. Zinc gluconate and the common cold: a controlled clinical study. J Int Med Res. 1992 Jun;20(3):234–246. doi: 10.1177/030006059202000305. [DOI] [PubMed] [Google Scholar]
  6. Korant B. D., Butterworth B. E. Inhibition by zinc of rhinovirus protein cleavage: interaction of zinc with capsid polypeptides. J Virol. 1976 Apr;18(1):298–306. doi: 10.1128/jvi.18.1.298-306.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mossad S. B., Macknin M. L., Medendorp S. V., Mason P. Zinc gluconate lozenges for treating the common cold. A randomized, double-blind, placebo-controlled study. Ann Intern Med. 1996 Jul 15;125(2):81–88. doi: 10.7326/0003-4819-125-2-199607150-00001. [DOI] [PubMed] [Google Scholar]
  8. Novick S. G., Godfrey J. C., Godfrey N. J., Wilder H. R. How does zinc modify the common cold? Clinical observations and implications regarding mechanisms of action. Med Hypotheses. 1996 Mar;46(3):295–302. doi: 10.1016/s0306-9877(96)90259-5. [DOI] [PubMed] [Google Scholar]
  9. Prandoni P., Lensing A. W., Cogo A., Cuppini S., Villalta S., Carta M., Cattelan A. M., Polistena P., Bernardi E., Prins M. H. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996 Jul 1;125(1):1–7. doi: 10.7326/0003-4819-125-1-199607010-00001. [DOI] [PubMed] [Google Scholar]
  10. Prasad A. S. Zinc: the biology and therapeutics of an ion. Ann Intern Med. 1996 Jul 15;125(2):142–144. doi: 10.7326/0003-4819-125-2-199607150-00012. [DOI] [PubMed] [Google Scholar]
  11. Salas M., Kirchner H. Induction of interferon-gamma in human leukocyte cultures stimulated by Zn2+. Clin Immunol Immunopathol. 1987 Oct;45(1):139–142. doi: 10.1016/0090-1229(87)90120-6. [DOI] [PubMed] [Google Scholar]
  12. Smith D. S., Helzner E. C., Nuttall C. E., Jr, Collins M., Rofman B. A., Ginsberg D., Goswick C. B., Magner A. Failure of zinc gluconate in treatment of acute upper respiratory tract infections. Antimicrob Agents Chemother. 1989 May;33(5):646–648. doi: 10.1128/aac.33.5.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Zarembo J. E., Godfrey J. C., Godfrey N. J. Zinc(II) in saliva: determination of concentrations produced by different formulations of zinc gluconate lozenges containing common excipients. J Pharm Sci. 1992 Feb;81(2):128–130. doi: 10.1002/jps.2600810205. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES